# Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

> **NCT00602706** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 76 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** sargramostim
- **DRUG:** melphalan
- **PROCEDURE:** autologous hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** samarium Sm 153 lexidronam pentasodium

## Key facts

- **NCT ID:** NCT00602706
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2003-06
- **Final completion:** 2010-07
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2011-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602706, "Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00602706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*